Post_template - Page 2 of 10

BioEUROPE, November 4–6, 2024, Stockholm, SE

Mark your calendars for BIOEurope in Stockholm, November 4–6, 2024! Schedule a one-on-one meeting with OncoOne’s CEO, Randolf Kerschbaumer, and CSO, Michael Thiele to learn about our oxMIF-targeting antibodies for inflammation and oncology, and the PreTarg-it® platform for targeted radiotherapy. Explore exciting partnering opportunities with

Publication: Imperial College London and OncoOne Unveil Latest Findings on ON104 Efficacy in Nephritis in PLoS One

We are delighted to present our latest findings in PLOS ONE, which highlight the therapeutic potential of our anti-oxMIF antibody ON104 in kidney disease! Our findings spotlight the exciting potential of targeting oxMIF in inflammatory kidney diseases. In a rat model of crescentic glomerulonephritis (CGN),

Festival of Biologics, October 15-17, 2024, Basel, CH

Are you attending the FestivalOfBiologics in Basel? Don’t miss our CSO, Michael Thiele, presenting “ON104: Pioneering Treatment for oxMIF-Driven Autoimmune Diseases”. It’s a fantastic opportunity to explore the potential of our lead candidate, the anti-oxMIF antibody ON104, as an innovative treatment for autoimmune conditions. Get

Krebsforschungslauf , October 5, 2024, Vienna, AT

Krebsforschungslauf 2024 – This year, we laced up for the first time, running with heart and purpose to support the fight against cancer! On October 5th, the Uni Campus Altes AKH turned into a vibrant running arena for a great cause. With the goal of

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics! Our platform for pre-targeted radioimmunotherapy is featured as the First Disclosure and cover story in this month’s AACR journal Molecular Cancer Therapeutics (MCT). Our innovative two-step regimen is set to revolutionize the delivery of

Bio Asia Taiwan, July 24-28, 2024, Taipei Nangang

Bio Asia-Taiwan is about to start! Don’t miss the chance to schedule a one-on-one meeting with OncoOne’s VP of CMC, Friedmund Bachmann. Attend his talk, “Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development,” on July 25, from 12.30 to 12:50 in

Publication: Brown University and OncoOne Publish Key Aspects of oxMIF Biology in Redox Biology.

Thrilled to share that Brown University and OncoOne have published key aspects of oxMIF biology in Redox Biology. Our most recent paper, “Redox-dependent plasticity of oxMIF facilitates its interaction with CD74 and therapeutic antibodies,” explores how MIF, undergoes oxidation to oxMIF by neutrophil-released myeloperoxidase (MPO).

Publication: Promising Results from Our PreTarg-it® Platform Published in AACR’s Molecular Cancer Therapeutics.

Thrilled to share a significant milestone: Our groundbreaking research paper on pretargeted radioimmunotherapy using the novel PreTarg-it® antibody ON105, titled “Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer,” is now published in the AACR

EULAR 2024, June 12-15, 2024, Vienna, AT

#SavetheDate: OncoOne’s Vice President of Preclinical and Translational R&D Christine Landlinger-Schubert, and Senior Scientist Maroua FERHAT will be attending EULAR2024 in Vienna. They will present a poster on our lead asset, ON104. This is a great opportunity to learn about the potential of our novel

Bio International Convention, June 3-6, 2024, San Diego, CA, US

Heading to BIO2024? Take the opportunity to schedule a one-on-one meeting with OncoOne’s CEO, Randolf Kerschbaumer, and CTO, Alexander Schinagl. Explore potential partnerships and learn about our pioneering anti-oxMIF antibody pipeline for treating cancer and chronic inflammatory diseases, as well as our PreTarg-it® technology for